82 Efficacy, Safety, and Biomarker Analysis of ICARUS-BREAST01: A Phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in Patients With HR+/HER2– Advanced Breast Cancer
ByBarbara Pistilli,Livia Pierotti,Magali Lacroix-Triki,Cecile Vicier,Jean-Sebastien Frenel,Véronique D’Hondt,Florence Dalenc,Thomas Bachelot,Agnes Ducoulombier,Marc-Antoine Benderra,Delphine Loirat,Didier Mayeur,Ghada B. Nachabeh,Andrea Sporchia,Fumitaka Suto,Stefan Michiels,Noemie Corcos,Fernanda Mosele,Fabrice André, Guillaime Montagnac